EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study

Meng Wang iD, Quanying Zhang iD, Zhe Shi, Ling Zhang, Jie Pan iD

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70450 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Meng Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China. Hauptthemen laut MEDLINE: TYK2 Kinase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

D‐2570 selectively binds to the pseudokinase domain of tyrosine kinase 2, which mediates the downstream cytokine signaling pathways involved in immune regulation. The safety, tolerability, pharmacokinetics, and pharmacodynamics of D‐2570 were evaluated in a randomized, double‐blind, placebo‐controlled phase I study conducted in healthy Chinese subjects. The study consisted of three parts: single ascending dose (D‐2570: 3–48 mg once daily) study, multiple ascending dose (D‐2570: 6–36 mg once daily for 10 days) study, and food effect (D‐2570: 9 mg) study. D‐2570 was rapidly absorbed, with peak plasma concentration at around 4 h and exposure increased sub‐proportional across the dose groups. Following multiple dosing, mean terminal elimination half‐lives at steady state ranged from 22.22 to 33.86 h, with modest area under curve accumulation (1.74‐ to 2.08‐fold) showing no dose dependence. A high‐fat meal increased area under the concentration time curve from time zero extrapolated to infinite time and maximum plasma concentration by 33% and 15% for the 9‐mg dose, with no significant effect on median time to maximum concentration. The inhibitory effect of D‐2570 on the release of interferon‐gamma induced by interleukin‐12/interleukin‐18 increased dose‐dependently in the range of 6–36 mg. No deaths or serious treatment‐emergent adverse events occurred, and all the adverse events were Grade 1 or 2 in severity. D‐2570 was well tolerated in healthy Chinese subjects, and its pharmacokinetic profile was characterized. These results provide the rationale for dose selection in future clinical trials and support advancing D‐2570 as a potential treatment option for autoimmune diseases mediated by tyrosine kinase 2. Trial Registration: Chinadrugtrials.org.cn (CTR20222168)

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TYK2 KinaseProtein Kinase InhibitorsHumansMaleAdultFemaleDouble-Blind MethodYoung AdultHealthy VolunteersAdministration, OralDose-Response Relationship, DrugFood-Drug InteractionsMiddle AgedHalf-LifeAdolescentArea Under CurveInterferon-gamma

Stichwörter der Autor:innen

D‐2570pharmacodynamicspharmacokineticsphase I clinical trialsafetytyrosine kinase 2 inhibitor

Substanzen

TYK2 KinaseTYK2 protein, humanProtein Kinase InhibitorsInterferon-gamma

Autor:innen und Institutionen

  • Department of Pharmacy, The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, People's Republic of China.
  • InventisBio Co., Ltd., Shanghai, People's Republic of China.

ORCID-Profile: Meng Wang, Quanying Zhang, Jie Pan

Zitieren

APA

Wang, M., Zhang, Q., Shi, Z., Zhang, L., & Pan, J. (2026). Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study. Clinical and Translational Science. https://doi.org/10.1111/cts.70450

Vancouver

Wang M, Zhang Q, Shi Z, Zhang L, Pan J. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study. Clinical and Translational Science. 2026. doi:10.1111/cts.70450

BibTeX
@article{Wang2026,
  author = {Wang, Meng and Zhang, Quanying and Shi, Zhe and Zhang, Ling and Pan, Jie},
  title = {Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral TYK2 Inhibitor D‐2570 in Healthy Subjects: A First‐in‐Human Phase I Study},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70450}
}
Kostenlos starten →